German biotech firm BioNTech on Monday said that second-quarter revenues more than doubled to 261 million euros ($302 million ...

BioNTech’s second-quarter earnings came in at a loss of 1.60 euros a share on revenue of €261 million ($302.1 million), ...

The company expects that the U.S. COVID-19 vaccination rate will be “maybe a couple of points lower” than the prior level of ...

BioNTech (BNTX) recently reported significant improvements in its financial performance, with quarterly sales nearly doubling compared to the previous year and a substantial reduction in net losses.

BioNTech SE BNTX +3.21% Get Free Report reported a second-quarter per-share loss of $1.82 (1.60 euros) on Monday, up from a loss of 3.36 euros reported a year ago, compared to beating the consensus ...

CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal ...

BioNTech (BNTX) stock gains as the company surpasses Q2 2025 forecasts with 103% YoY revenue growth, thanks mainly to Pfizer ...

Continued execution of BioNTech’s oncology strategy with focus on two pan-tumor programs including two announced transactions: mRNA-based cancer immunotherapy candidates and BNT327, a bispecific antib ...

BioNTech said a partnership with Bristol Myers Squibb is expected to further strengthen its financial position with $1.5 billion expected to be reflected in its cash position for the current quarter.

Germany’s BioNTech has reported revenues for the second quarter 2025 of 260.8 million euros ($302 million), more than double ...

While many of us may think of the cold and flu viruses as a fall or winter nuisance, summer colds are actually quite common.